Neuren Pharmaceuticals’ Lucrative Year with DAYBUE Success

Neuren Pharmaceuticals Limited (AU:NEU) has released an update.

Neuren Pharmaceuticals has reported strong financial performance following the successful U.S. launch of DAYBUE™, the first treatment for Rett syndrome, with 2023 net sales reaching US$177 million in under 9 months and projected 2024 sales between US$370 to US$420 million. The company’s expanded partnership with Acadia Pharmaceuticals has generated significant revenue, including a US$100 million upfront payment, royalties, and milestone payments, totaling A$271.6 million. Additionally, Neuren is leading in developing treatments for rare neurological conditions, with promising Phase 2 trial results for NNZ-2591 in Phelan-McDermid and Pitt Hopkins syndromes, and is preparing for further clinical trials while enjoying a robust financial standing with A$243.1 million in cash and short-term investments.

For further insights into AU:NEU stock, check out TipRanks’ Stock Analysis page.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

More Related Articles

Info icon

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.